drugset / Trial / NCT01104480
Tocilizumab for Relapsing Polychondritis
NaSingle-groupOpen-labelTreatment
Summary
This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-07
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |